Department:
University of Maryland Greenebaum Cancer Center
UMGCC Research Program:
Experimental Therapeutics Program
Education/Training:
College Degree:
B.S., cum laude, Rensselaer Polytechnic Institute
Medical Degree:
The Albany Medical College 1982
Residency:
Internship in Internal Medicine 1982-1983, Naval Hospital, San Diego, CA
Residency in Internal Medicine 1984-1986
Naval Hospital, San Diego, CA
Fellowship:
Hematology/Oncology Fellowship 1987-1990,
Naval Hospital, San Diego, CA
Certification:
Internal Medicine
Medical Oncology
Contact
Information:
Mailing Address:
Division of Hematology and Oncology
Director, Medical Thoracic Oncology
22 South Greene St.
Baltimore, MD 21201-1595
Email:
medelman@umm.edu
Phone:
410-328-2703
Fax:
410-328-0805
Research Interests:
My research concentrates on the development of new approaches to the management of lung cancer and other thoracic malignancies including the preclinical and clinical evaluation of new agents and combinations. In collaboration with basic scientists and other clinicians we are evaluating a number of new agents including the novel antitubulin agent, benzoylphenylurea and the cyclin dependent kinase inhibitor UCN-01. Approaches developed on the basis of laboratory work and early clinical trials at the University of Maryland have been taken forward into larger clinical settings including the Cancer and Leukemia Group B and the Radiation Therapy Oncology Group.
Currently, we are particularly interested in approaches that individualize chemotherapy for specific patients based upon variables including analysis of the tumor based upon circluating cancer cells as well as evaluation of tumor avidity for antineoplastic radiopharmaceuticals.
Publications:
Edelman MJ, Gandara DR. Sequential Chemotherapy: Rationale and Clinical Trial Design in Advanced Non-Small Cell Carcinoma. Clinical Lung Cancer 1:122-127, 1999.
Edelman MJ, Gandara DR, Meyers FJ, Ishii R, OMahony M, Uhrich M, Lauder I, Houston J, Gietzen DW. Serotonergic Blockade in the Treatment of the Cancer Anorexia-Cachexia Syndrome. Cancer 86:684-8, 1999.
Edelman MJ, Bauer K, Khanwani S, Van Echo D, Karp J. Clinical and Pharmacologic Study of Tributyrin: An Oral Butyrate Prodrug. Cancer Chemotherapy and Pharm 51:439-444, 2003.
Edelman MJ, Quam H, Mullins B. Interactions of Gemcitabine, Carboplatin and Paclitaxel in Molecularly Defined Non-Small Cell Lung Cancer Cell Lines. Cancer Chemo and Pharm 48:141-4, 2001.
Edelman MJ, Chansky K, Crowley J, Leigh B, Gaspar L, Livingston R, Gandara D. Phase II (SWOG 9713) Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small Cell Lung Cancer. J Clin Oncol 2004 Jan 1; 22(1): 127-132.
Edelman MJ, Clark J, Chansky K, Albain K, Gandara DR. Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer: Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel (SWOG 9806). Clin Cancer Res (in press, 2004).
Edelman MJ, Smith R, Kendall J, Doyle LA, Hausner P, Kalra K, Bedor M, Bisaccia S. Phase II trial of the novel retinoid, bexarotene, and gemcitabine/carboplatin in advanced non-small cell lung cancer 2005, 23:5774-8. J Clin Oncol
Edelman MJ. The role of bortezomib in chemoradiotherapy of non-small cell lung cancer. Clin Lung Ca 2005, 7 suppl 2: S64-S66.
Bellil Y and Edelman MJ. Bronchogenic carcinoma in solid organ transplant recipients. Current Treatment Options in Oncology. 2006, 7:77-81.
Edelman MJ. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer, Sem Oncol 32 (suppl 10):S3-S8, 2006.
Edelman MJ, Sekine I, Tamura T, Saijo N. Geographic Variation in the Second Line Treatment of Non-small-Cell Lung Cancer. Sem Oncol (in press, 2006)
